Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
bioAffinity Technologies, Inc. (BIAF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: BIAF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -35.4% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 19.81M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 310427 | Beta 3.12 | 52 Weeks Range 0.25 - 3.16 | Updated Date 03/30/2025 |
52 Weeks Range 0.25 - 3.16 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.91 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -119.41% | Operating Margin (TTM) -87.08% |
Management Effectiveness
Return on Assets (TTM) -69.78% | Return on Equity (TTM) -151.52% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5683067 | Price to Sales(TTM) 0.5 |
Enterprise Value 5683067 | Price to Sales(TTM) 0.5 | ||
Enterprise Value to Revenue 0.61 | Enterprise Value to EBITDA -0.21 | Shares Outstanding 15476600 | Shares Floating 8582450 |
Shares Outstanding 15476600 | Shares Floating 8582450 | ||
Percent Insiders 29.55 | Percent Institutions 2.47 |
Analyst Ratings
Rating 4 | Target Price 6 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
bioAffinity Technologies, Inc.
Company Overview
History and Background
bioAffinity Technologies, Inc. was founded in 2014. They are a cancer diagnostics company focused on early detection and treatment monitoring of lung cancer and other diseases.
Core Business Areas
- CyPath Lung: A non-invasive test for early detection of lung cancer, using flow cytometry to analyze sputum samples.
- Drug Development: Research and development of targeted cancer therapies based on proprietary porphyrin technology.
Leadership and Structure
Maria Zannes serves as the President and CEO. The company has a board of directors and a management team focused on research, development, and commercialization.
Top Products and Market Share
Key Offerings
- CyPath Lung: A diagnostic test for early-stage lung cancer detection, using patient-collected sputum samples. Market share is still developing. Competitors include Exact Sciences (EXAS) with their Oncotype DX test, and various liquid biopsy companies like Guardant Health (GH).
Market Dynamics
Industry Overview
The cancer diagnostics market is experiencing rapid growth, driven by increasing incidence of cancer, advancements in technology, and a growing focus on early detection.
Positioning
bioAffinity Technologies aims to differentiate itself with its non-invasive sputum-based CyPath Lung test, targeting a segment of the lung cancer diagnostics market that favors less invasive procedures. Their advantage is ease of collection for the patient.
Total Addressable Market (TAM)
The lung cancer diagnostics market is estimated to be in the billions of dollars annually. bioAffinity's position depends on adoption of CyPath Lung, which is still early stage.
Upturn SWOT Analysis
Strengths
- Non-invasive diagnostic test (CyPath Lung)
- Proprietary porphyrin technology
- Potential for early-stage cancer detection
Weaknesses
- Limited commercialization history
- Dependence on CyPath Lung's success
- Relatively small size compared to established competitors
- Requirement for FDA approval.
Opportunities
- Expansion of CyPath Lung into new markets
- Development of additional diagnostic tests
- Partnerships with pharmaceutical companies for drug development
- Increasing awareness of early cancer detection
Threats
- Competition from established diagnostic companies
- Regulatory hurdles
- Technological advancements by competitors
- Reimbursement challenges from payers
Competitors and Market Share
Key Competitors
- EXAS
- GH
- NVS
- MRK
Competitive Landscape
bioAffinity Technologies competes with larger, more established companies in the cancer diagnostics market. Its competitive advantage lies in its non-invasive CyPath Lung test and porphyrin technology.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by significant investment in R&D and clinical trials.
Future Projections: Future growth is tied to successful commercialization of CyPath Lung and advancements in drug development.
Recent Initiatives: Recent initiatives include expanding the commercial reach of CyPath Lung and pursuing collaborations with research institutions.
Summary
bioAffinity Technologies is an early-stage cancer diagnostics company with a promising non-invasive lung cancer detection test. Its success depends on successful commercialization, overcoming regulatory hurdles, and competing with larger industry players. The company's proprietary technology and focus on early detection provide potential for growth, but also carries high risk in the competitive landscape.
Similar Companies
- EXAS
- GH
- PACB
- ILMN
Sources and Disclaimers
Data Sources:
- SEC filings, Company website, Analyst reports, Press releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Please consult with a qualified financial advisor before making any investment decisions. Market Share data is an estimate based on available information and may not be precise. Financial Metrics are limited based on the limited operating data
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About bioAffinity Technologies, Inc.
Exchange NASDAQ | Headquaters San Antonio, TX, United States | ||
IPO Launch date 2022-09-01 | Founder, President, CEO & Director Ms. Maria Zannes J.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 75 | Website https://www.bioaffinitytech.com |
Full time employees 75 | Website https://www.bioaffinitytech.com | ||
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.